Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced a key manufacturing milestone for its ONC010 program, producing approximately 952 grams of the B4 precursor component at kilogram scale. This achievement, completed in collaboration with Dalton Pharma Services, supports the advancement of the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology toward future formulation development, GMP production, and planned clinical studies.
The kilogram-scale production of B4 material is a critical step in establishing a scalable manufacturing process for clinical supply. By demonstrating the ability to produce the precursor at this scale, Onco-Innovations strengthens its integrated development strategy and reduces risks associated with later-stage manufacturing. The company's ONC010 program targets solid tumors through a novel mechanism that inhibits PNKP, an enzyme involved in DNA repair, potentially enhancing the effectiveness of cancer therapies.
This advancement comes as Onco-Innovations also announced the engagement of InvestorBrandNetwork (IBN) to provide market awareness, corporate communications, and digital media services through September 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 and intends to apply an unused US$80,000 balance returned from a prior market awareness engagement toward the consideration. IBN is a part of the Dynamic Brand Portfolio that delivers access to a vast network of wire solutions, article syndication to 5,000+ outlets, and social media distribution. For more details, the full press release is available at https://ibn.fm/BbWHd.
The ability to produce B4 at kilogram scale is important for the oncology field because it moves ONC010 closer to clinical testing. PNKP inhibitors represent a promising approach to cancer treatment by disrupting DNA repair pathways in tumor cells, potentially making them more susceptible to radiation and chemotherapy. If successful, ONC010 could offer new options for patients with solid tumors that are resistant to current treatments.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. More information is available at https://oncoinnovations.com/.
The manufacturing milestone also underscores the importance of chemistry, manufacturing, and controls (CMC) partnerships in drug development. By working with Dalton Pharma Services, Onco-Innovations leveraged expertise to produce high-quality material suitable for future GMP production. This progress is vital for advancing the ONC010 program toward regulatory filings and clinical trials, which could ultimately benefit patients and the broader oncology community.
